Hospira voices dedication to lowering costs

Hospira is dedicated to finding ways to reduce the costs of health care, it has asserted.

Pete Baker, vice-president and general manager of the company’s commercial service operations, made this comment after it was announced the firm had signed a deal with MedAssets to renew its agreement for infusion devices.

The five-year contract is for intravenous solutions and equipment – as well as infusion devices – and will run through until June 30th 2014.

Mr Baker noted both businesses are committed to improving patient and healthcare safety.

“We look forward to continuing our work with MedAssets’ member healthcare institutions to drive these goals,” he said.

President of MedAssets supply chain systems added the company is pleased to expand its relationship with Hospira.

As part of its flexible, customer-driven approach to reducing supply expenses for its members, Hospira’s solutions and equipment would provide extra options for the firm’s members, he concluded.

Last month, the Food and Drug Adminstration approved Hospira’s 500 mg vial of azithromycin for injection in the ADD-Vantage System.